Alliance for Multispecialty Research, LLC. | Layton Research Center

Research site

(Unclaimed)

Location

2132 N 1700 W Suite 200, Layton, Utah, United States of America

Site insights

Top conditions

Top treatments

LY573144

Tirzepatide

Lasmiditan

Survodutide

Retatrutide

Ixekizumab

LY2439821

BI 456906

Parent organization

This site is a part of Alliance for Multispecialty Research, LLC.

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 15 total trials

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition...

Enrolling

Weight Gain

Obesity

Drug: Tirzepatide

Drug: Placebo

Locations recently updated

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participan...

Enrolling

Psoriasis

Overweight or Obesity

Drug: Tirzepatide

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants

The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germ...

Active, not recruiting

Pneumococcal Disease

Biological: 15-valent pneumococcal conjugate vaccine (PCV15)

Biological: PG4

Locations recently updated

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

This study is open to adults who are at least 18 years old and have a body mass index (BMI) of 27 kg/m2 or more. People can take part if they have ca...

Active, not recruiting

Obesity

Combination Product: Placebo

Combination Product: survodutide

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

This is a Phase 2/3 randomized, observer-blinded, placebo-controlled, age de-escalation trial to evaluate the safety and immunogenicity of 2 primary...

Active, not recruiting

COVID-19

Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)

Other: Placebo

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Active, not recruiting

Atherosclerotic Cardiovascular Disease (ASCVD)

Chronic Kidney Disease (CKD)

Drug: Retatrutide

Drug: Placebo